Predict patient health risk and measure responses to treatment over time with SomaSignal™ tests.

Through SomaSignal tests, providers receive a real-time snapshot of disease risk and determine whether a person is headed for a severe health event.

Utilizing our next-generation testing, providers can leverage a single blood sample to scan for a multitude of biomarkers that indicate future risk, improving outcomes and saving costs.


SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic Operating Co., Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory SomaLogic and SomaSignal are trademarks of SomaLogic Operating Co., Inc © 2022 SomaLogic Operating Co., Inc.